HAT-I: A Potential Drug Target for Cancer (P11328)

Target Name: Histone acetyltransferase (HAT)

NCBI ID: P11328

Histone acetyltransferase (HAT)

Other Name(s): None

HAT-I: A Potential Drug Target for Cancer

Histone acetyltransferase (HAT) is an enzyme involved in the histone modification of chromatin, which plays a crucial role in regulating gene expression and DNA replication. The nonspecific subtype of HAT, HAT-I, has been identified as a drug potential target and a biomarker for various diseases, including cancer.

The histone modification system is a complex process that involves the addition of acetyl groups to the histones, which are small proteins that make up the nucleosome, the basic unit of chromatin. These modifications play a significant role in the regulation of gene expression and the maintenance of cellular processes such as cell growth, development, and division.

HAT is a key enzyme involved in the histone modification process. It catalyzes the transfer of an acetyl group from the amino acid lysine to the carbon atom of the histone. This process not only modifies the physical properties of the chromatin but also influences the accessibility of the chromatin to transcription factors, which are responsible for regulating gene expression.

The nonspecific subtype of HAT, HAT-I, is a key enzyme in the histone modification system. It is highly conserved and has been shown to play a critical role in the regulation of gene expression, cell growth, and division. HAT-I is expressed in a variety of tissues and cells and is involved in the regulation of gene expression by target proteins.

HAT-I has been shown to play a role in the regulation of cell growth and division. For example, HAT-I has been shown to be involved in the regulation of cell cycle progression, and it has been shown to promote the G1 phase of the cell cycle by activating the G1-specific kinase, p21. Additionally, HAT-I has been shown to play a role in the regulation of cell division, and it has been shown to promote the formation of polyploid cells by inhibiting the activity of the tumor suppressor protein, p53.

HAT-I has also been shown to be involved in the regulation of inflammation. For example, HAT-I has been shown to play a role in the regulation of the immune response by activating the transcription factor Nrf2, which is involved in the regulation of gene expression that is necessary for the development of cancer.

In addition to its role in the regulation of cell growth and division, HAT-I has also been shown to play a role in the regulation of cellular processes such as cell survival and apoptosis. For example, HAT-I has been shown to play a role in the regulation of cell survival by activating the Bcl-2 protein, which is a survival protein that can prevent cell death. Additionally, HAT-I has been shown to play a role in the regulation of apoptosis, the process by which cells die , by activating the protein Bad, which is involved in the regulation of apoptosis.

HAT-I has also been shown to play a role in the regulation of gene expression by modifying the chromatin structure. For example, HAT-I has been shown to add acetyl groups to the carbon atoms of the histones, which can alter the accessibility of the chromatin to transcription factors. Additionally, HAT-I has been shown to remove histone tails, which can also alter the accessibility of the chromatin.

Due to its role in the regulation of gene expression and the maintenance of cellular processes, HAT-I is a potential drug target and a biomarker for various diseases, including cancer. For example, HAT-I has been shown to be involved in the regulation of cancer cell growth and has been shown to promote the formation of polyploid cells in cancer cells. Additionally, HAT-I has been shown to play a role in the regulation of cancer cell apoptosis, and has been shown to

Protein Name: Histone Acetyltransferase (HAT) (nonspecified Subtype)

The "Histone acetyltransferase (HAT) Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Histone acetyltransferase (HAT) comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets